초록접수 현황
| 17F-105 | 포스터 발표 |
Prognostic Factors Affecting Survival after Pulmonary Metastatectomy from Hepatocellular Carcinoma
Mi Hyoung Moon, Jae Kil Park, Young Kyu Moon, Kyung Soo Kim, Hyung Joo Park, Sook Whan Sung, Seok Whan Moon
Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary’s Hospital, The Catholic University College of Medicine, Seoul, Republic of Korea
Purpose : Pulmonary metastatectomy has become the standard therapy for various metastatic diseases, including hepatocellular carcinoma (HCC). However, few data have been available about lung metastatectomy for HCC. The purpose of this study is to review the outcomes of metastatectomy in HCC patients in single-center.
Methods : From Seoul St.Mary’s clinical data warehouse, we extracted patients with pathologically confirmed, surgically resected metastatic HCC patients, a total of 45 patients between 1997 and 2017. The observation period was terminated on 30 June 2017. Primary outcome was overall survival, counting from the date of initiating HCC treatment. Because of the numbers are small, we did univariate analysis only.
Results : Among 48 patients, 33 patients received any type of hepatic resection, and 29 patients received liver transplantation before pulmonary metastatectomy. Time from the first day of liver treatment to the day of first pulmonary metastatectomy was median 25 months, and overall survival was 52 months. Pulmonary metastatectomy was done by VATS in 39 patients, thoracotomy in 9 patients. Type of resection was wedge resection in 43 patients, and segmentectomy or lobectomy in 5 patients. Univariate analysis showed that whether the primary HCC is controlled either by TACE, chemotherapy, or surgery or not at the time of pulmonary metastatectomy was significant for overall survival (p= 0.008). However, having systemic metastasis or not was not significant prognostic factors in this population (p =0.13).
Conclusion : Under the circumstances of primary liver HCC is controlled with any treatment modality (surgery, liver transplantation, TACE, etc), pulmonary metastatectomy should be done even other metastasis exist.
Methods : From Seoul St.Mary’s clinical data warehouse, we extracted patients with pathologically confirmed, surgically resected metastatic HCC patients, a total of 45 patients between 1997 and 2017. The observation period was terminated on 30 June 2017. Primary outcome was overall survival, counting from the date of initiating HCC treatment. Because of the numbers are small, we did univariate analysis only.
Results : Among 48 patients, 33 patients received any type of hepatic resection, and 29 patients received liver transplantation before pulmonary metastatectomy. Time from the first day of liver treatment to the day of first pulmonary metastatectomy was median 25 months, and overall survival was 52 months. Pulmonary metastatectomy was done by VATS in 39 patients, thoracotomy in 9 patients. Type of resection was wedge resection in 43 patients, and segmentectomy or lobectomy in 5 patients. Univariate analysis showed that whether the primary HCC is controlled either by TACE, chemotherapy, or surgery or not at the time of pulmonary metastatectomy was significant for overall survival (p= 0.008). However, having systemic metastasis or not was not significant prognostic factors in this population (p =0.13).
Conclusion : Under the circumstances of primary liver HCC is controlled with any treatment modality (surgery, liver transplantation, TACE, etc), pulmonary metastatectomy should be done even other metastasis exist.
첨부파일 : Figure.zip
책임저자: Seok Whan Moon
Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary’s Hospital, The Catholic University College of Medicine, Seoul, Republic of Korea
발표자: Mi Hyoung Moon, E-mail : sophiamoon@hanmail.net